HSBC has maintained its ‘Underweight’ stance on Ranbaxy but has raised its target to Rs 420. The adjusted net profit is higher than estimates due to favorable rupee impact on trade. Sales were led by higher than expected first-to-file sales of generic Lipitor in the US. Key risk to the underweight call is faster approvals, and higher than estimated earnings in Lipitor post exclusivity.